search button

Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center

  • Authors:
    • Yichen Zhu
    • Jing Xiao
    • Yuwen Guo
    • Jun Lin
    • Lei Zhang
    • Ye Tian

  • View Affiliations

  • Published online on: July 30, 2015     https://doi.org/10.3892/mco.2015.615
  • Pages: 1387-1391
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to assess the safety and efficacy of gemcitabine plus cisplatin/carboplatin (GC/GCa) chemotherapy in renal transplantation (RT) patients with urothelial carcinoma (UC). We reviewed the records of 12 RT patients with metastatic or locally advanced UC who received chemotherapy at our institution since January, 2013. All the patients received intravenous gemcitabine (800 mg/m2) on days 1, 8 and 15, plus cisplatin (70 mg/m2) or carboplatin (area under the curve = 5) on day 2, every 28 days. A total of 10 patients completed all the cycles, while 1 patient discontinued treatment due to disease progression and 1 patient discontinued due to non‑medical reasons. In total, 12 patients received a median of four cycles of chemotherapy. The overall response rate was 50% (4/8 cases) in patients with measurable lesions. At the time of the study, 5 patients had succumbed to the disease (overall survival, 9.2 months), while 7 patients remained alive (follow‑up time, 13.3 months). The most common toxicities were myelosuppression and gastrointestinal effects. Therefore, the GC/GCa regimen was found to be effective and tolerable in RT patients with UC. However, further studies involving more patients and control groups are required to confirm our results.
View References

Related Articles

Journal Cover

November-2015
Volume 3 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu Y, Xiao J, Guo Y, Lin J, Zhang L and Tian Y: Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center. Mol Clin Oncol 3: 1387-1391, 2015
APA
Zhu, Y., Xiao, J., Guo, Y., Lin, J., Zhang, L., & Tian, Y. (2015). Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center. Molecular and Clinical Oncology, 3, 1387-1391. https://doi.org/10.3892/mco.2015.615
MLA
Zhu, Y., Xiao, J., Guo, Y., Lin, J., Zhang, L., Tian, Y."Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center". Molecular and Clinical Oncology 3.6 (2015): 1387-1391.
Chicago
Zhu, Y., Xiao, J., Guo, Y., Lin, J., Zhang, L., Tian, Y."Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center". Molecular and Clinical Oncology 3, no. 6 (2015): 1387-1391. https://doi.org/10.3892/mco.2015.615